AmyriAD picks up Alzheimer’s drug that began as a trial control

Dutch biotech AmyriAD Therapeutics has added a second clinical-stage drug in six weeks, buying worldwide rights to the Alzheimer's candidate AD04 from Miami-based ADvantage Therapeutics on undisclosed terms. It plans a Phase 2b trial in mild Alzheimer's disease, though ADvantage's own European Phase 2b is paused.

ADVERTISEMENT

Why it matters: Originally, AD04 was meant to be a control, not a treatment. Back in 2010-2013, a decade before it became a candidate in a Phase 2b trial, Vienna-based AFFiRiS tested amyloid vaccine AD02 against it in AFF006, a 332-patient Phase 2 trial in Europe.

AD04 is the vaccine’s aluminum adjuvant, an immune booster. AFF006’s two control groups received it alone, at 1 mg or 2 mg. The 2 mg group did significantly better than at least one other arm of the trial on measures including cognition and daily function, in unadjusted comparisons. Exploratory post hoc analyses of the control patients showed signs of slower cognitive decline and less hippocampal volume loss.

“Cognitive decline threatens people’s independence, relationships and daily lives. Addressing it requires more treatment options across different biological mechanisms and stages of disease,” said K. Ranga Rama Krishnan, chairman of the board and CEO of AmyriAD, in a press release announcing the deal.

Zoom in: ADvantage told the EU clinical trials register it paused the ADVANCE study in Austria and Poland in January to align it with a planned U.K. study. The halt notices cite a sponsor decision, report no change in the trial’s balance of benefits and risks, and say no patients were on treatment at those sites.

Reality check: AD04’s evidence so far is exploratory. AFF006 had no inactive placebo. When the results were presented at the 7th Clinical Trials on Alzheimer’s Disease (CTAD) conference, attendees asked why 2 mg of adjuvant given with the vaccine had not slowed decline, AlzForum reported. AFFiRiS’s Achim Schneeberger suggested the vaccine peptide might interfere with the adjuvant.

A 2025 paper by authors including ADvantage shareholders found the signal survived correction for multiple testing but called post hoc results hypothesis-generating.

Robert Howard, professor of old age psychiatry at University College London, led a U.K. trial in which the anti-inflammatory minocycline did not significantly slow decline in mild Alzheimer’s. “I’d say that the high failure rate of drugs in this area should lead everyone to exercise a healthy degree of scepticism about the prospects for success for this drug,” he told European Biotechnology.

“However, I’d temper this with two points,” he said. “Firstly, nobody can tell if a drug is going to work or not without conducting an adequately powered phase 2/3 trial and it is completely correct for the sponsor to be planning this. Second, many successful treatments in medicine were discovered by serendipity and I wouldn’t let the unusual way in which AD04 came to attention as a potential Alzheimer’s treatment count against it.”

The big picture: AmyriAD is expanding through share deals. On October 7, it acquired Recognify Life Sciences in an all-share deal with milestone payments, and it describes itself as building its portfolio “through disciplined, equity-based acquisitions.” Recognify’s drug, inidascamine, had missed its primary endpoint in a Phase 2b in schizophrenia-related cognitive impairment.

Recognify’s majority owner, AtaiBeckley, which Lilly bought this year in a deal worth up to $3.8 billion (€3.3 billion at the time), took an undisclosed stake in AmyriAD in return.

“Following our acquisition of Recognify Life Sciences, AD04 further expands our cognition pipeline alongside lead program Ismidenon,” Krishnan said.

What’s next: AmyriAD’s release gives no timing, location or funding for its Phase 2b. The test is whether the company can get a placebo-controlled trial of AD04 underway, by restarting ADVANCE or starting over.


Editor’s note: Neither AmyriAD nor ADvantage responded to requests for comment by the time this story was published.

YOU DON`T WANT TO MISS ANYTHING?

Sign up for our newsletter!